Jointown Pharm receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Metrics to compare | 600998 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship600998PeersSector | |
|---|---|---|---|---|
P/E Ratio | 11.8x | 11.3x | −0.5x | |
PEG Ratio | −0.36 | 0.01 | 0.00 | |
Price/Book | 0.9x | 0.9x | 2.6x | |
Price / LTM Sales | 0.1x | 0.4x | 3.1x | |
Upside (Analyst Target) | 39.9% | 32.2% | 52.5% | |
Fair Value Upside | Unlock | 21.8% | 6.0% | Unlock |
Jointown Pharmaceutical Group Co., Ltd engages in pharmaceutical distribution and supply chain business in China and internationally. It is also involved in general agency brand promotion; pharmaceutical industrial self-production and OEM; and pharmaceutical new retail and ten-thousand store alliance plan businesses. In addition, the company provides medical health and technology value-added services; and digital logistics and supply chain solutions. The company was founded in 1999 and is headquartered in Wuhan, China.